KR102131588B1 - 간세포 암종 (hcc) 의 치료를 위해 사용되는 6-옥소-1,6-디히드로-피리다진 유도체 - Google Patents
간세포 암종 (hcc) 의 치료를 위해 사용되는 6-옥소-1,6-디히드로-피리다진 유도체 Download PDFInfo
- Publication number
- KR102131588B1 KR102131588B1 KR1020157014482A KR20157014482A KR102131588B1 KR 102131588 B1 KR102131588 B1 KR 102131588B1 KR 1020157014482 A KR1020157014482 A KR 1020157014482A KR 20157014482 A KR20157014482 A KR 20157014482A KR 102131588 B1 KR102131588 B1 KR 102131588B1
- Authority
- KR
- South Korea
- Prior art keywords
- oxo
- dihydro
- methyl
- benzyl
- ylmethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12007494 | 2012-11-02 | ||
| EP12007494.3 | 2012-11-02 | ||
| PCT/EP2013/002998 WO2014067610A1 (en) | 2012-11-02 | 2013-10-04 | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150079942A KR20150079942A (ko) | 2015-07-08 |
| KR102131588B1 true KR102131588B1 (ko) | 2020-07-08 |
Family
ID=47143496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157014482A Expired - Fee Related KR102131588B1 (ko) | 2012-11-02 | 2013-10-04 | 간세포 암종 (hcc) 의 치료를 위해 사용되는 6-옥소-1,6-디히드로-피리다진 유도체 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20150283137A1 (https=) |
| EP (1) | EP2914264B1 (https=) |
| JP (1) | JP6255028B2 (https=) |
| KR (1) | KR102131588B1 (https=) |
| CN (1) | CN104768553A (https=) |
| AR (1) | AR093318A1 (https=) |
| AU (1) | AU2013339823B2 (https=) |
| BR (1) | BR112015008279A2 (https=) |
| CA (1) | CA2890273C (https=) |
| DK (1) | DK2914264T3 (https=) |
| ES (1) | ES2646913T3 (https=) |
| HK (1) | HK1211869A1 (https=) |
| HR (1) | HRP20171295T1 (https=) |
| HU (1) | HUE035483T2 (https=) |
| IL (1) | IL238536B (https=) |
| LT (1) | LT2914264T (https=) |
| MX (1) | MX354518B (https=) |
| NO (1) | NO2914264T3 (https=) |
| PL (1) | PL2914264T3 (https=) |
| PT (1) | PT2914264T (https=) |
| RS (1) | RS56485B1 (https=) |
| RU (1) | RU2650679C2 (https=) |
| SG (1) | SG11201503214YA (https=) |
| SI (1) | SI2914264T1 (https=) |
| WO (1) | WO2014067610A1 (https=) |
| ZA (1) | ZA201503924B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015022782A1 (ja) | 2013-08-14 | 2015-02-19 | 有限会社ジャパン通商 | 水耕栽培システム、および該水耕栽培システムと発泡スチロール製ハウスとを備えた植物工場 |
| US20220288068A1 (en) * | 2019-07-10 | 2022-09-15 | Merck Patent Gmbh | Pharmaceutical preparation |
| EP4045009A4 (en) * | 2019-10-14 | 2023-11-01 | Olatec Therapeutics LLC | METHOD FOR TREATING BREAST CANCER |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009007074A1 (de) * | 2007-07-12 | 2009-01-15 | Merck Patent Gmbh | Pyrimidinyl-pyridazinonderivate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2010078897A1 (en) * | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof |
-
2013
- 2013-10-04 PL PL13776720T patent/PL2914264T3/pl unknown
- 2013-10-04 ES ES13776720.8T patent/ES2646913T3/es active Active
- 2013-10-04 PT PT137767208T patent/PT2914264T/pt unknown
- 2013-10-04 KR KR1020157014482A patent/KR102131588B1/ko not_active Expired - Fee Related
- 2013-10-04 SI SI201330832T patent/SI2914264T1/sl unknown
- 2013-10-04 SG SG11201503214YA patent/SG11201503214YA/en unknown
- 2013-10-04 EP EP13776720.8A patent/EP2914264B1/en active Active
- 2013-10-04 CA CA2890273A patent/CA2890273C/en active Active
- 2013-10-04 CN CN201380057293.0A patent/CN104768553A/zh active Pending
- 2013-10-04 RS RS20171129A patent/RS56485B1/sr unknown
- 2013-10-04 LT LTEP13776720.8T patent/LT2914264T/lt unknown
- 2013-10-04 MX MX2015005265A patent/MX354518B/es active IP Right Grant
- 2013-10-04 HK HK16100004.6A patent/HK1211869A1/xx unknown
- 2013-10-04 HU HUE13776720A patent/HUE035483T2/hu unknown
- 2013-10-04 RU RU2015120692A patent/RU2650679C2/ru active
- 2013-10-04 US US14/440,181 patent/US20150283137A1/en not_active Abandoned
- 2013-10-04 DK DK13776720.8T patent/DK2914264T3/en active
- 2013-10-04 BR BR112015008279A patent/BR112015008279A2/pt not_active Application Discontinuation
- 2013-10-04 WO PCT/EP2013/002998 patent/WO2014067610A1/en not_active Ceased
- 2013-10-04 JP JP2015541023A patent/JP6255028B2/ja active Active
- 2013-10-04 HR HRP20171295TT patent/HRP20171295T1/hr unknown
- 2013-10-04 AU AU2013339823A patent/AU2013339823B2/en active Active
- 2013-10-04 NO NO13776720A patent/NO2914264T3/no unknown
- 2013-11-01 AR ARP130103990A patent/AR093318A1/es not_active Application Discontinuation
-
2015
- 2015-04-30 IL IL238536A patent/IL238536B/en active IP Right Grant
- 2015-06-01 ZA ZA2015/03924A patent/ZA201503924B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009007074A1 (de) * | 2007-07-12 | 2009-01-15 | Merck Patent Gmbh | Pyrimidinyl-pyridazinonderivate |
Also Published As
| Publication number | Publication date |
|---|---|
| MX354518B (es) | 2018-03-08 |
| EP2914264A1 (en) | 2015-09-09 |
| JP6255028B2 (ja) | 2017-12-27 |
| PT2914264T (pt) | 2017-11-14 |
| EP2914264B1 (en) | 2017-08-09 |
| US20150283137A1 (en) | 2015-10-08 |
| AU2013339823B2 (en) | 2018-01-04 |
| RS56485B1 (sr) | 2018-01-31 |
| DK2914264T3 (en) | 2017-09-11 |
| HRP20171295T1 (hr) | 2017-10-20 |
| LT2914264T (lt) | 2017-11-10 |
| JP2015536957A (ja) | 2015-12-24 |
| ZA201503924B (en) | 2020-11-25 |
| BR112015008279A2 (pt) | 2017-07-04 |
| WO2014067610A1 (en) | 2014-05-08 |
| KR20150079942A (ko) | 2015-07-08 |
| SI2914264T1 (sl) | 2017-12-29 |
| CA2890273A1 (en) | 2014-05-08 |
| AR093318A1 (es) | 2015-05-27 |
| PL2914264T3 (pl) | 2017-12-29 |
| NO2914264T3 (https=) | 2018-01-06 |
| ES2646913T3 (es) | 2017-12-18 |
| IL238536B (en) | 2019-01-31 |
| HK1211869A1 (en) | 2016-06-03 |
| CA2890273C (en) | 2021-10-26 |
| SG11201503214YA (en) | 2015-05-28 |
| IL238536A0 (en) | 2015-06-30 |
| RU2650679C2 (ru) | 2018-04-17 |
| MX2015005265A (es) | 2015-07-17 |
| RU2015120692A (ru) | 2016-12-27 |
| HUE035483T2 (hu) | 2018-05-02 |
| AU2013339823A1 (en) | 2015-06-18 |
| CN104768553A (zh) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015360006B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative | |
| MX2014010982A (es) | Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancerosa con otros compuestos antitumorales. | |
| KR102131588B1 (ko) | 간세포 암종 (hcc) 의 치료를 위해 사용되는 6-옥소-1,6-디히드로-피리다진 유도체 | |
| US20190388423A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor | |
| KR102157501B1 (ko) | 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 ｍｅｋ 억제제와의 조합 | |
| CN105848658A (zh) | 具有抗癌活性的6-氧代-1,6-二氢-哒嗪衍生物与吉非替尼的组合 | |
| HK1227693A1 (en) | Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20250703 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE Effective date: 20250703 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20250703 |